Disease · MONDO_0001056

gastric cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gastric cancer. Diseases, record MONDO_0001056. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001056

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gastric cancer; Open Targets
Open Targets ID: MONDO_0001056; Open Targets
Other names: Ca lesser curvature - stomach, GC, cancer of stomach, gastric cancer risk after h. pylori infection, gastric cancer, somatic, malignant gastric neoplasm, malignant gastric tumor, malignant gastric tumour, malignant neoplasm of lesser curve of stomach, malignant neoplasm of stomach, malignant neoplasm of the stomach, malignant stomach neoplasm, malignant tumor of body of stomach, malignant tumor of greater curve of stomach, malignant tumor of lesser curve of stomach, malignant tumor of stomach, malignant tumor of the stomach, malignant tumour of body of stomach, malignant tumour of greater curve of stomach, malignant tumour of lesser curve of stomach, malignant tumour of stomach, malignant tumour of the stomach, stomach cancer; Open Targets
Disease Ontology: DOID:10534; Disease Ontology
NCI Thesaurus: C9331; NCI Thesaurus
Highest stage of its drugs: Approval, for 11 of its 375 drugs, from PMDA and TTD; Open Targets

Drugs375

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TEGAFUR	CHEMBL20883	Small molecule	Approval	PMDA	75	74	32	Drugs and targets
GIMERACIL	CHEMBL1730601	Small molecule	Approval	PMDA	55	54	7	Drugs and targets
TRASTUZUMAB	CHEMBL1201585	Antibody	Approval	PMDA	55	52	49	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Approval	PMDA	48	47	47	Drugs and targets
RAMUCIRUMAB	CHEMBL1743062	Antibody	Approval	PMDA	20	19	19	Drugs and targets
ZOLBETUXIMAB	CHEMBL2109427	Antibody	Approval	PMDA	6	5	5	Drugs and targets
VONOPRAZAN FUMARATE	CHEMBL2064032	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
ANAMORELIN HYDROCHLORIDE	CHEMBL2103794	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
ESOMEPRAZOLE MAGNESIUM	CHEMBL5314366	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
LENIOLISIB	CHEMBL3643413	Small molecule	Approval	TTD	1	0	0	Drugs and targets

1 to 10 of 375

See all 375 drugs

Targets302

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	23	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
ERBB2	Epidermal growth factor receptor	22	Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 cross-linking agent; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-2 binding agent	Approval	https://conductscience.org/library/genes/2064	Drugs and targets
KDR	Vascular endothelial growth factor receptor	22	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
PDCD1	Programmed cell death protein 1	17	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	16	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	14	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
TUBA1A	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	14	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets

1 to 10 of 302

See all 302 targets

Trials1,024

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 36 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02872116	Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer	Phase 3	2,031	2022-06-28	Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma	CAPECITABINE, FLUOROURACIL, IPILIMUMAB, LEUCOVORIN CALCIUM, NIVOLUMAB, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01968109	An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Phase 1/2	1,482	2026-01-06	Neoplasms by Site	NIVOLUMAB, RELATLIMAB	Its record names the disease	ClinicalTrials.gov
NCT01928394	A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors	Phase 1/2	1,163	2020-03-24	Advanced or Metastatic Solid Tumors	COBIMETINIB, IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00400179	A Safety and Efficacy Study in Patients With Gastric Cancer	Phase 3	1,053	2012-04-23	Gastric Cancer	CISPLATIN, FLUOROURACIL	Its record names the disease	ClinicalTrials.gov
NCT00296335	Trial of Adjuvant Chemotherapy for Gastric Cancer	Phase 3	855	2014-02-27	Stomach Cancer	CISPLATIN, DOXIFLURIDINE, MITOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT01774786	A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer	Phase 3	780	2018-02-14	Gastric Cancer	CAPECITABINE, CISPLATIN, FLUOROURACIL, PERTUZUMAB, TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00548548	A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer	Phase 3	774	2012-01-19	Adenocarcinoma	BEVACIZUMAB, CAPECITABINE, CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT03615326	Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)	Phase 3	738	2025-03-17	Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma	CAPECITABINE, CISPLATIN, FLUOROURACIL, OXALIPLATIN, PEMBROLIZUMAB, TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00940225	Study of Cabozantinib (XL184) in Adults With Advanced Malignancies	Phase 2	730	2024-04-25	Solid Tumors, Cancer	CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT02322593	Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer	Phase 3	711	2021-12-20	Gastric Cancer	CISPLATIN, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,024

See all 1,024 trials

Comparisons in its trials124

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
S-1/Cisplatin vs 5-FU/Cisplatin: serious adverse events	257 of 521	248 of 508	1,029	NCT00400179	Trial comparisons
Mitomycin Plus Short-term Fluoropyrimidine vs Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati: serious adverse events	3 of 422	5 of 425	847	NCT00296335	Trial comparisons
Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause	299 of 385	318 of 388	773	NCT01774786	Trial comparisons
Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events	178 of 385	156 of 388	773	NCT01774786	Trial comparisons
Bevacizumab vs Placebo: serious adverse events	134 of 386	137 of 381	767	NCT00548548	Trial comparisons
TAS-118/Oxaliplatin vs S-1/Cisplatin: deaths from any cause	22 of 352	8 of 348	700	NCT02322593	Trial comparisons
TAS-118/Oxaliplatin vs S-1/Cisplatin: serious adverse events	155 of 352	159 of 348	700	NCT02322593	Trial comparisons
Everolimus 10mg / Daily vs Placebo: serious adverse events	210 of 437	89 of 215	652	NCT00879333	Trial comparisons
Fluoropyrimidine/Cisplatin (FP) vs Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H): serious adverse events	81 of 290	106 of 294	584	NCT01041404	Trial comparisons
mFOLFOX6 + Zolbetuximab vs mFOLFOX6+ Placebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs)	278 of 279	277 of 278	557	NCT03504397	Trial comparisons

1 to 10 of 124

See all 124 comparisons in its trials

Papers from its trials507

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41747221	RESULT	1	PubMed
40762544	RESULT	1	PubMed
40083701	RESULT	1	PubMed
39836033	RESULT	1	PubMed
39822559	RESULT	1	PubMed
39282917	RESULT	1	PubMed
39031824	RESULT	1	PubMed
38718741	RESULT	1	PubMed
38240092	RESULT	1	PubMed
38051328	RESULT	2	PubMed

1 to 10 of 507

See all 507 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001056

GET https://conductscience.org/api/diseases/v1/MONDO_0001056/drugs?page=2

API reference For AI assistants